Fig. 5

Function of erythrocyte-cancer hybrid membrane. A Confocal fluorescence imaging and quantitative analysis of CPCC and CPCCM NPs (50 μg/mL) in RAW264.7 cells (Bule: nucleus, red: Ce6). B Blood fluorescence intensity (Ce6: Ex/Em = 400/653 nm) of Ce6, CPCC, and CPCCM (2.5 mg/kg) over time. C Pharmacokinetic curves of Ce6, CPCC, and CPCCM. D Confocal fluorescence imaging and quantitative analysis of CPCC NPs (50 μg/mL) coated with the different membrane in MDA-MB-231 and SMC cells. E Bio-distribution of CPCC and CPCCM NPs (2.5 mg/kg) at 0, 1, 2, 6, 12, 24 h. F Fluorescence distribution of major organs after 48 h post-injection (2.5 mg/kg CPCC and CPCCM NPs). G Fluorescence intensity quantitative analysis of major organs after 48 h post-injection. Data were shown as mean ± SD, n = 3. ANOVA was used to assess statistical significance. *p < 0.05, ***p < 0.001